VARIZIG

This brand name is authorized in United States. It is also authorized in Canada, Estonia.

Active ingredients

The drug VARIZIG contains one active pharmaceutical ingredient (API):

1	Human varicela zoster immunoglobulin UNII 33T61IWL27 - HUMAN VARICELLA-ZOSTER IMMUNE GLOBULIN
	Human varicella zoster immunoglobulin contains mainly immunoglobulin G (IgG) with a specifically high content of antibodies against varicella-zoster virus. It is used for prophylaxis against varicella zoster virus (VZV) infection.
	Read more about Human varicela zoster immunoglobulin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VARIZIG Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J06BB03	Varicella/zoster immunoglobulin	J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BB Specific immunoglobulins
Discover more medicines within J06BB03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02442183
EE	Ravimiamet	1706420
US	FDA, National Drug Code	53270-0126, 70257-126, 70504-0126